Stago Group said today that it completed its acquisition of point-of-care blood diagnostics platform developer HemoSonics.
Charlottesville, Va.-based HemoSonics developed the Quanta Hemostasis Analyzer, which is designed to measure treatable aspects of hemostasis in approximately 15 minutes using its sonic estimation of elasticity via resonance (SEER) technology.
Financial details of the acquisition were not disclosed. The transaction is part of Stago’s efforts to diversity its portfolio of medical devices, according to the company.
“This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patients outcomes worldwide,” chairman of the board, Lionel Viret, said in prepared remarks.
“Stago brings exceptional expertise in the field of thrombosis and hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting” HemoSonics president & CEO Timothy Fischer added.
Ferghana Partners was HemoSonics’ exclusive financial advisor for the transaction.